Artelo Biosciences, Inc. (ARTL) stock declined over -2.48% intraday to trade at $0.30 a share on NASDAQ. The stock opened with a loss of -4.76% at $0.3 and touched an intraday high of $0.323, falling -3.23% against the last close of $0.31. The stock went to a low of $0.294 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Artelo Biosciences, Inc. (NASDAQ: ARTL) stock price is $0.3 as of the last check on Tuesday, July 5. During the trading session, ARTL stock reached the peak price of $0.323 while $0.294 was the lowest point it dropped to.
The NASDAQ listed ARTL is part of Pharmaceuticals industry that operates in the broader Health Care sector. Artelo Biosciences, Inc. , a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system.
Mr. Gregory D. Gorgas M.B.A.
Pres, CEO, CFO, Treasurer, Sec. & Director
Dr. Andrew Yates Ph.D.
Sr. VP & Chief Scientific Officer
Dr. Steven D. Reich
Chief Medical Officer
Mr. Jason H. Baybutt
Sr. VP of Fin.
ARTL stock traded closed the last session at $0.302, which is $-0.01 or -2.48% lower than its previous close of $0.31. ARTL's current trading price is 7.73% lower than its 52-week high of $1.32 where as its distance from 52-week low of 0.28% is -77.10%.
Number of ARTL employees currently stands at -. ARTL operates from 505 Lomas Santa Fe, Suite 160, Solana Beach, CA 92075, United States.
Official Webiste of $ARTL is: https://www.artelobio.com
ARTL stock volume for the day was 400,937 shares while in the previous session number of ARTL shares traded was 400,937 . The average number of ARTL shares traded daily for last 3 months was 1.38 Million.
The percentage change in ARTL stock occurred in the recent session was -2.48% while the dollar amount for the price change in ARTL stock was $-0.01.
In the recent session, the day high for ARTL stock was $0.323 while the low for ARTL stock touched on the day was $0.294.
The market value of ARTL currently stands at 13.07 Million with its latest stock price at $0.3 and 42.3 Million of its shares outstanding.